Skip to main content

Vaccine clinical trials at UC Davis

7 research studies open to eligible people

Showing trials for
  • A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

    “By signing up, you can help answer some of the biggest questions for getting back to life safely”

    open to eligible people ages 18-29

    The purpose of this study is to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in individuals immunized with the Moderna COVID-19 vaccine.

    Sacramento, California and other locations

  • A Study of the Effect of an Oral Vaccine on the Digestive System

    open to eligible females ages 18-49

    This study evaluates the effect of an oral typhoid vaccine on disruption of the intestinal barrier and response of the immune system. Intestinal and whole-body responses will be measured in all participants before and after the vaccine.

    Davis, California

  • A Study of the Experimental Cytomegalovirus (CMV) Vaccine (HB-101) in Kidney Transplant Patients

    open to eligible people ages 18-99

    HB-101 is a bivalent recombinant vaccine against human CMV infection. This is a randomized, placebo-controlled, phase 2 study to assess the safety, reactogenicity, immunogenicity, and efficacy of HB-101 in CMV-Seronegative patients receiving a kidney transplant from a CMV-Seropositive living donor and CMV-Seropositive patients.Patients enrolled should have a living donor kidney transplantation ideally planned between two to four months after the first injection of study drug (HB-101 or placebo).

    Sacramento, California and other locations

  • Are you pregnant? Participate in a vaccine study trying to protect babies from Respiratory Syncytial Virus!

    “Pass on what's important: You’ll give them love in lots of ways. Could protection from RSV be one of them?”

    open to eligible females ages 18-49

    This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.

    Sacramento, California and other locations

  • Impact of Immunosuppression Adjustment on Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients (ADIVKT)

    open to eligible people ages 18 years and up

    Immunocompromised individuals, such as solid organ transplant (SOT) recipients are at high risk of COVID-19 associated complications and mortality. Retrospective studies so far have shown that a majority of SOT recipients did not develop appreciable anti-spike antibody response after a first, second, or even third dose of mRNA vaccine. Treatment with antimetabolites was associated with poor vaccine response. The goal of this study is 1) examine whether transient immunosuppression reduction improves the immune response to a third dose of SARS-CoV-2 mRNA vaccine in kidney transplant recipients and 2) to assess the safety of immunosuppression reduction before and after third dose SARS-CoV-2 mRNA vaccination.

    Sacramento, California

  • Study of high dose/low dose influenza vaccine to effectively stop heart or lung-related problems

    “Does high-dose influenza (“flu”) vaccine safely reduce heart or lung-related problems compared to the standard-dose flu vaccine?”

    open to eligible people ages 18 years and up

    INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.

    Sacramento, California and other locations

  • Study of Immune Response to Pneumococcal Vaccine in Splenic Injury Patients

    “How effective is vaccination in those who have sustained an injury to their spleen or undergone a surgical procedure to remove their spleen?”

    open to eligible people ages 18-65

    Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.

    Sacramento, California

Last updated: